Skip to content

KPV Tripeptide

KPV (Lys-Pro-Val) is the C-terminal tripeptide of α-melanocyte-stimulating hormone. Its qualified Open Enzyme evidence supports PepT1-mediated uptake and an NF-κB assay response in specific cell systems; it does not establish gout efficacy, synovial exposure, or a clinical delivery route.

Evidence relevant to gout

Dalmasso et al. measured KPV transport through human PepT1 in Caco2-BBE intestinal epithelial cells and Jurkat T cells. The reported KPV transport constants were approximately 160 µM in the epithelial system and 700 µM in Jurkat cells. In the Caco2-BBE assay, extracellular KPV concentrations in the nanomolar range reduced IL-1β-induced NF-κB reporter activation; 10 nM was the lowest tested effective concentration used as the engineering proxy in COMP-042. These are In Vitro observations in the named models (PMID 18061177); 10 nM is not an intracellular IC50, target-engagement threshold, or gout-effective concentration.

NF-κB contributes to inflammatory priming in the gout cascade, so a PepT1-dependent KPV effect in a gout-relevant macrophage is plausible but remains a Mechanistic Extrapolation. The qualified evidence on this page does not establish direct NLRP3-assembly inhibition by KPV, activity against monosodium urate crystals, or an effect in human gout. See the NLRP3 exploit map for the pathway context.

Sourcing and delivery

For research use, the material must be a chemically defined KPV preparation with its sequence or chemical form, counterion, purity, identity, endotoxin burden, solvent, and stability recorded. These are experimental-material requirements, not consumer-sourcing guidance.

Delivery remains unresolved:

  • PepT1 uptake: demonstrated in Caco2-BBE and Jurkat systems (In Vitro); functional uptake in resting or MSU-activated synovial macrophages is unmeasured.
  • Joint exposure: no qualified route-specific KPV pharmacokinetic measurement establishes useful extracellular or intracellular exposure in a human joint.
  • COMP-042 route spaces: the intra-articular range is arithmetic from declared dose and compartment-volume assumptions; subcutaneous and oral values are named pharmacokinetic design spaces. They are not observed synovial concentrations or route qualifications.
  • Intracellular stability: uncharacterized in the relevant cells and not modeled by COMP-042.
  • Clinical safety: no route-specific clinical safety package is cited here. This page is a research record, not a dosing or treatment protocol.

GSDMD pore entry

COMP-042 estimates the passive GSDMD-pore contribution relative to the 10 nM extracellular cell-assay proxy; it does not model intracellular efficacy. Under the declared route spaces, A1 is GREEN for intra-articular, YELLOW for subcutaneous, and RED for oral delivery. The full A2 grid retains favorable heuristic corners—including two of nine moderate-PepT1 and one of nine high-PepT1 intra-articular combinations—but healthy-cell uptake, synovial-macrophage PepT1 activity, and concurrent PepT1 transport in pore-forming cells remain unmeasured or unmodeled.

Because KPV is framed as acting upstream of pore formation, the useful intervention window is uncertain; pathway order alone does not prove that pore-mediated entry is too late. KPV is therefore a confounded probe of pore selectivity. A prequalified transporter-orphan payload with a downstream intracellular target would isolate the pore contribution more directly. Mechanistic Extrapolation.

Research conjecture — KPV could modify gout-relevant inflammatory priming before pore formation

Grounded premises: KPV enters the epithelial and Jurkat cell systems studied through PepT1 and reduces IL-1β-induced NF-κB reporter activation at extracellular nanomolar concentrations (In Vitro; Dalmasso et al.). NF-κB is part of gout-relevant inflammatory priming (Mechanistic Extrapolation; NLRP3 exploit map).

Novel leap: If a gout-relevant macrophage admits KPV through PepT1 at a useful exposure before or during priming, KPV might reduce later inflammasome output. No direct evidence tests this sequence in gout or synovial macrophages.

Why it matters: This would define a KPV opportunity independent of the more weakly constrained pore-selectivity hypothesis.

Discriminating observation: In a prespecified MSU-relevant macrophage system, cross KPV timing and concentration with PepT1-on/off conditions; measure intracellular KPV, NF-κB priming, pro-IL-1β, inflammasome/caspase/GSDMD outputs, viability, and washout controls.

Falsification path

Two questions should be tested separately:

  1. KPV biology: Does exact KPV produce a reproducible, PepT1-dependent change in gout-relevant priming at a measured intracellular exposure? A result that lacks uptake, concentration response, or mechanism-proximal change does not advance the conjecture.
  2. Pore-delivery physics: Validation §1.32 uses a prequalified transporter-orphan tracer for the primary pore-on/off test and KPV only as a pore-on/off × PepT1-on/off uptake comparator. It has no KPV efficacy endpoint.

A negative result kills only the tested material, exposure, timing, cell system, and mechanism claim. It does not decide every α-MSH-derived peptide or the wider transporter-orphan pore-delivery hypothesis.